Xenetic Revenue Per Share vs Current Deferred Revenue Analysis

XBIO Stock

USD 4.04 0.07 1.70%

Xenetic Biosciences financial indicator trend analysis is more than just analyzing Xenetic Biosciences current accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Xenetic Biosciences is a good investment. Please check the relationship between Xenetic Biosciences Revenue Per Share and its Current Deferred Revenue accounts. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Xenetic Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

To learn how to invest in Xenetic Stock, please use our How to Invest in Xenetic Biosciences guide.

Revenue Per Share vs Current Deferred Revenue

Revenue Per Share vs Current Deferred Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Xenetic Biosciences Revenue Per Share account and Current Deferred Revenue. At this time, the significance of the direction appears to have strong relationship.

The correlation between Xenetic Biosciences' Revenue Per Share and Current Deferred Revenue is 0.69. Overlapping area represents the amount of variation of Revenue Per Share that can explain the historical movement of Current Deferred Revenue in the same time period over historical financial statements of Xenetic Biosciences, assuming nothing else is changed. The correlation between historical values of Xenetic Biosciences' Revenue Per Share and Current Deferred Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Revenue Per Share of Xenetic Biosciences are associated (or correlated) with its Current Deferred Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Current Deferred Revenue has no effect on the direction of Revenue Per Share i.e., Xenetic Biosciences' Revenue Per Share and Current Deferred Revenue go up and down completely randomly.

Correlation Coefficient

0.69

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Revenue Per Share

The amount of revenue generated by a company per share of stock, calculated by dividing total revenue by the average number of shares outstanding.

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.

Most indicators from Xenetic Biosciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Xenetic Biosciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Xenetic Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

To learn how to invest in Xenetic Stock, please use our How to Invest in Xenetic Biosciences guide.At this time, Xenetic Biosciences' Selling General Administrative is very stable compared to the past year. As of the 26th of November 2024, Enterprise Value Over EBITDA is likely to grow to 0.86, while Issuance Of Capital Stock is likely to drop 0.00.

Xenetic Biosciences fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Common Stock Total Equity	Non Current Liabilities Total	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Common Stock	Current Deferred Revenue	Non Currrent Assets Other	Net Receivables	Common Stock Shares Outstanding	Other Current Assets	Other Stockholder Equity	Short Term Debt	Intangible Assets
Total Assets		0.18	0.24	0.4	0.92	-0.53	-0.46	-0.43	0.44	0.47	0.62	0.47	0.05	0.6	0.53	-0.71	0.56	0.35	0.0	0.18	0.25	0.02	0.15	0.24	-0.33	-0.18
Short Long Term Debt Total	0.18		0.01	0.41	-0.01	0.64	0.28	0.69	0.14	-0.23	0.47	-0.23	0.31	0.47	0.51	0.21	-0.24	0.86	0.83	-0.6	-0.11	-0.5	0.07	-0.82	0.83	0.64
Other Current Liab	0.24	0.01		0.83	-0.03	-0.28	0.19	-0.16	0.73	-0.19	0.29	-0.19	0.36	0.27	0.63	-0.43	-0.05	-0.02	0.32	-0.16	0.63	-0.03	0.82	0.03	-0.2	-0.27
Total Current Liabilities	0.4	0.41	0.83		0.04	-0.08	0.29	0.06	0.86	-0.27	0.57	-0.27	0.24	0.55	0.88	-0.42	-0.12	0.27	0.64	-0.31	0.61	-0.26	0.83	-0.25	0.1	0.0
Total Stockholder Equity	0.92	-0.01	-0.03	0.04		-0.6	-0.72	-0.56	0.11	0.73	0.35	0.73	-0.08	0.34	0.18	-0.65	0.77	0.22	-0.28	0.4	0.04	0.23	-0.14	0.45	-0.45	-0.23
Property Plant And Equipment Net	-0.53	0.64	-0.28	-0.08	-0.6		0.6	0.97	-0.23	-0.56	0.03	-0.56	0.22	0.06	0.01	0.81	-0.63	0.43	0.6	-0.73	-0.24	-0.61	-0.17	-0.91	0.94	0.77
Net Debt	-0.46	0.28	0.19	0.29	-0.72	0.6		0.66	0.35	-1.0	0.36	-1.0	0.26	0.35	0.39	0.43	-0.97	0.12	0.5	-0.72	0.23	-0.67	0.31	-0.67	0.5	0.36
Retained Earnings	-0.43	0.69	-0.16	0.06	-0.56	0.97	0.66		-0.08	-0.61	0.19	-0.61	0.22	0.23	0.19	0.77	-0.66	0.45	0.64	-0.77	-0.14	-0.73	-0.03	-0.95	0.95	0.81
Accounts Payable	0.44	0.14	0.73	0.86	0.11	-0.23	0.35	-0.08		-0.34	0.72	-0.34	0.23	0.72	0.9	-0.54	-0.18	0.11	0.43	-0.18	0.65	-0.4	0.74	-0.05	-0.15	0.0
Cash	0.47	-0.23	-0.19	-0.27	0.73	-0.56	-1.0	-0.61	-0.34		-0.32	1.0	-0.24	-0.31	-0.35	-0.43	0.97	-0.08	-0.46	0.7	-0.24	0.61	-0.31	0.63	-0.45	-0.28
Non Current Assets Total	0.62	0.47	0.29	0.57	0.35	0.03	0.36	0.19	0.72	-0.32		-0.32	0.32	0.99	0.88	-0.35	-0.25	0.55	0.45	-0.37	0.27	-0.66	0.27	-0.34	0.14	0.32
Cash And Short Term Investments	0.47	-0.23	-0.19	-0.27	0.73	-0.56	-1.0	-0.61	-0.34	1.0	-0.32		-0.24	-0.31	-0.35	-0.43	0.97	-0.08	-0.46	0.7	-0.24	0.61	-0.31	0.63	-0.45	-0.28
Common Stock Total Equity	0.05	0.31	0.36	0.24	-0.08	0.22	0.26	0.22	0.23	-0.24	0.32	-0.24		0.32	0.32	-0.14	-0.27	0.64	0.54	-0.31	-0.14	-0.23	-0.06	-0.33	0.19	0.19
Non Current Liabilities Total	0.6	0.47	0.27	0.55	0.34	0.06	0.35	0.23	0.72	-0.31	0.99	-0.31	0.32		0.87	-0.31	-0.25	0.54	0.45	-0.36	0.26	-0.69	0.27	-0.36	0.17	0.37
Total Liab	0.53	0.51	0.63	0.88	0.18	0.01	0.39	0.19	0.9	-0.35	0.88	-0.35	0.32	0.87		-0.4	-0.23	0.45	0.64	-0.39	0.5	-0.56	0.64	-0.35	0.17	0.24
Property Plant And Equipment Gross	-0.71	0.21	-0.43	-0.42	-0.65	0.81	0.43	0.77	-0.54	-0.43	-0.35	-0.43	-0.14	-0.31	-0.4		-0.51	-0.05	0.09	-0.49	-0.27	-0.34	-0.23	-0.63	0.7	0.47
Total Current Assets	0.56	-0.24	-0.05	-0.12	0.77	-0.63	-0.97	-0.66	-0.18	0.97	-0.25	0.97	-0.27	-0.25	-0.23	-0.51		-0.13	-0.45	0.63	0.0	0.6	-0.12	0.66	-0.51	-0.34
Common Stock	0.35	0.86	-0.02	0.27	0.22	0.43	0.12	0.45	0.11	-0.08	0.55	-0.08	0.64	0.54	0.45	-0.05	-0.13		0.73	-0.43	-0.28	-0.38	-0.19	-0.61	0.58	0.51
Current Deferred Revenue	0.0	0.83	0.32	0.64	-0.28	0.6	0.5	0.64	0.43	-0.46	0.45	-0.46	0.54	0.45	0.64	0.09	-0.45	0.73		-0.59	0.05	-0.5	0.28	-0.77	0.72	0.54
Non Currrent Assets Other	0.18	-0.6	-0.16	-0.31	0.4	-0.73	-0.72	-0.77	-0.18	0.7	-0.37	0.7	-0.31	-0.36	-0.39	-0.49	0.63	-0.43	-0.59		-0.35	0.67	-0.26	0.84	-0.7	-0.5
Net Receivables	0.25	-0.11	0.63	0.61	0.04	-0.24	0.23	-0.14	0.65	-0.24	0.27	-0.24	-0.14	0.26	0.5	-0.27	0.0	-0.28	0.05	-0.35		-0.1	0.83	0.07	-0.22	-0.26
Common Stock Shares Outstanding	0.02	-0.5	-0.03	-0.26	0.23	-0.61	-0.67	-0.73	-0.4	0.61	-0.66	0.61	-0.23	-0.69	-0.56	-0.34	0.6	-0.38	-0.5	0.67	-0.1		-0.12	0.7	-0.57	-0.77
Other Current Assets	0.15	0.07	0.82	0.83	-0.14	-0.17	0.31	-0.03	0.74	-0.31	0.27	-0.31	-0.06	0.27	0.64	-0.23	-0.12	-0.19	0.28	-0.26	0.83	-0.12		-0.06	-0.05	-0.19
Other Stockholder Equity	0.24	-0.82	0.03	-0.25	0.45	-0.91	-0.67	-0.95	-0.05	0.63	-0.34	0.63	-0.33	-0.36	-0.35	-0.63	0.66	-0.61	-0.77	0.84	0.07	0.7	-0.06		-0.95	-0.7
Short Term Debt	-0.33	0.83	-0.2	0.1	-0.45	0.94	0.5	0.95	-0.15	-0.45	0.14	-0.45	0.19	0.17	0.17	0.7	-0.51	0.58	0.72	-0.7	-0.22	-0.57	-0.05	-0.95		0.76
Intangible Assets	-0.18	0.64	-0.27	0.0	-0.23	0.77	0.36	0.81	0.0	-0.28	0.32	-0.28	0.19	0.37	0.24	0.47	-0.34	0.51	0.54	-0.5	-0.26	-0.77	-0.19	-0.7	0.76

Click cells to compare fundamentals

Xenetic Biosciences Account Relationship Matchups

Xenetic Biosciences fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	21.5M	13.2M	19.8M	14.7M	10.6M	18.0M
Other Current Liab	484.0K	609.5K	1.0M	785.8K	568.8K	997.5K
Total Current Liabilities	1.4M	936.9K	1.4M	1.1M	809.6K	1.6M
Total Stockholder Equity	17.2M	12.2M	18.4M	13.6M	9.8M	13.7M
Net Debt	(10.3M)	(11.5M)	(18.2M)	(13.1M)	(9.0M)	(9.4M)
Retained Earnings	(166.0M)	(176.9M)	(182.5M)	(189.1M)	(193.2M)	(202.9M)
Accounts Payable	931.1K	327.4K	362.5K	287.4K	240.8K	228.8K
Cash	10.4M	11.5M	18.2M	13.1M	9.0M	7.7M
Non Current Assets Total	10.5M	810.0K	1.1M	1.1M	1.0M	967.4K
Cash And Short Term Investments	10.4M	11.5M	18.2M	13.1M	9.0M	7.7M
Common Stock Total Equity	9.0K	9.7K	6.1K	8.8K	7.9K	7.5K
Liabilities And Stockholders Equity	21.5M	13.2M	19.8M	14.7M	10.6M	18.0M
Total Liab	4.3M	964.0K	1.4M	1.1M	809.6K	769.1K
Total Current Assets	11.1M	12.4M	18.7M	13.7M	9.6M	8.9M
Common Stock	6.1K	8.8K	13.5K	15.2K	1.5K	1.5K
Non Currrent Assets Other	1.2M	782.9K	1.1M	1.1M	1.0M	697.2K
Common Stock Shares Outstanding	285.2K	639.2K	1.0M	1.4M	1.5M	1.6M
Other Current Assets	722.1K	225K	252.4K	556.1K	603.8K	617.8K
Other Stockholder Equity	183.0M	188.9M	200.7M	202.5M	202.8M	162.6M
Net Tangible Assets	(2.6M)	8.0M	12.2M	18.4M	21.2M	22.2M
Retained Earnings Total Equity	(145.9M)	(153.2M)	(166.0M)	(176.9M)	(159.2M)	(167.2M)
Capital Surpluse	165.2M	168.2M	188.2M	194.1M	223.3M	157.1M
Property Plant Equipment	27.8K	5.0K	757.0	27.0K	24.3K	43.7K
Other Assets	705.7K	1.2M	810.0K	1.1M	1.3M	679.4K
Net Invested Capital	17.2M	12.2M	18.4M	13.6M	9.8M	10.9M
Net Working Capital	9.7M	11.4M	17.3M	12.6M	8.8M	9.9M
Capital Stock	8.9K	11.5K	16.2K	18.0K	3.3K	3.2K

Pair Trading with Xenetic Biosciences

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Xenetic Biosciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Xenetic Biosciences will appreciate offsetting losses from the drop in the long position's value.

Moving against Xenetic Stock

0.37

ROIV

Roivant Sciences

Pair Corr

The ability to find closely correlated positions to Xenetic Biosciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Xenetic Biosciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Xenetic Biosciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Xenetic Biosciences to buy it.

The correlation of Xenetic Biosciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Xenetic Biosciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Xenetic Biosciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Xenetic Biosciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Xenetic Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Xenetic Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Xenetic Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Xenetic Biosciences Stock:

How To Invest In Xenetic

Details

Is Xenetic Stock a good investment?

Details

What is Xenetic Biosciences' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Xenetic Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

To learn how to invest in Xenetic Stock, please use our How to Invest in Xenetic Biosciences guide.

You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Xenetic Biosciences. If investors know Xenetic will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Xenetic Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.66)

Revenue Per Share

1.638

Quarterly Revenue Growth

0.116

Return On Assets

(0.29)

Return On Equity

(0.49)

The market value of Xenetic Biosciences is measured differently than its book value, which is the value of Xenetic that is recorded on the company's balance sheet. Investors also form their own opinion of Xenetic Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Xenetic Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Xenetic Biosciences' market value can be influenced by many factors that don't directly affect Xenetic Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Xenetic Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Xenetic Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Xenetic Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Xenetic Revenue Per Share vs Current Deferred Revenue Analysis

Revenue Per Share vs Current Deferred Revenue

Revenue Per Share vs Current Deferred Revenue Correlation Analysis

Correlation Coefficient

Revenue Per Share

Current Deferred Revenue

Xenetic Biosciences fundamental ratios Correlations

Xenetic Biosciences Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Xenetic Biosciences fundamental ratios Accounts

Pair Trading with Xenetic Biosciences

Moving against Xenetic Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Cash
Non Current Liabilities Total	+ 0.99	Non Current Assets Total
Retained Earnings	+ 0.97	Property Plant And Equipment Net
Total Current Assets	+ 0.97	Cash
Total Current Assets	+ 0.97	Cash And Short Term Investments
Short Term Debt	+ 0.95	Retained Earnings

Cash And Short Term Investments	- 1.0	Net Debt
Cash	- 1.0	Net Debt
Total Current Assets	- 0.97	Net Debt
Short Term Debt	- 0.95	Other Stockholder Equity
Other Stockholder Equity	- 0.95	Retained Earnings
Other Stockholder Equity	- 0.91	Property Plant And Equipment Net